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Background: Fourteen countries in East and Southern Africa have
engaged in national programs to accelerate the provision of
voluntary medical male circumcision (VMMC) since 2007. Devices
have the potential to accelerate VMMC programs by making the
procedure easier, quicker, more efﬁcient, and widely accessible.
Methods: Pilot Implementation studies were conducted in Mozam-
bique, South Africa, and Zambia. The primary objective of the studies
was to assess the safety of PrePex device procedures when conducted
by nurses and clinical ofﬁcers in adults and adolescent males (13–17
years, South Africa only) with the following end points: number and
grade of adverse events (AEs); pain-related AEs measured using visual
analog score; device displacements/self-removals; time to complete
wound healing; and procedure times for device placement and removal.
Results: A total of 1401 participants (1318 adult and 83 adolescent
males) were circumcised using the PrePex device across the 3
studies. Rates of moderate/severe AEs were low (1.0%; 2.0%; and
2.8%) in the studies in Mozambique, Zambia, and South Africa,
respectively. Eight early self-removals of 1401 (0.6%) were
observed, all required corrective surgery. High rates of moderate/
severe pain-related AEs were recorded especially at device removal
in South Africa (34.9%) and Mozambique (59.5%). Ninety percent
of participants were healed at day 56 postplacement.
Discussion: The study results from the 3 countries suggest that the
implementation of the PrePex device using nonphysician health care
workers is both safe and feasible, but better pain control at device
removal needs to be put in place to increase the comfort of VMMC
clients using the PrePex device.
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BACKGROUND
Three randomized controlled trials have demonstrated
that male circumcision reduces the risk of heterosexually
acquired HIV infection in men by 60%.1–3 Fourteen countries
in East and Southern Africa have engaged in national programs
to accelerate the provision of voluntary medical male circum-
cision (VMMC) since 2007. VMMC is a 1-time intervention
resulting in lifelong protection from HIV infection in men.
However, despite the compelling evidence, the progress of
scaling up VMMC across the 14 countries has been variable. It
is estimated that by December 2013, 6 million male circum-
cisions had been conducted against a target of 20.3 million.4,5
Male circumcision devices have the potential to accel-
erate VMMC programs by making the procedure easier,
quicker, more efﬁcient, and widely accessible.6–8
One promising device is PrePex, a nonsurgical circum-
cision device, developed by Circ MedTech. It is an elastic
collar compression device, which works through slow com-
pression of the foreskin between an outer elastic ring and inner
hard surface between glans and foreskin, which occludes the
circulation and produces tissue devitalization and necrosis.9 The
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device is left in place for 7 days during which the compressed
foreskin becomes necrotic and then is removed by cutting with
scissors; the device can be applied and the foreskin and the
device can be removed without injected local anesthetic.9
The World Health Organization Technical Advisory
Group (WHO TAG) reviewed 8 published and unpublished
studies of the PrePex device in January, 2013. Based on the
available data from Rwanda, Zimbabwe, and Uganda, the TAG
provided conditional prequaliﬁcation for use of the PrePex device
in men aged 18 or older, but recommended that skilled surgical
backup be available to manage severe complications.7,10–13
After the recommendations by WHO and the TAG
outlined in the Framework for Clinical Evaluation of Devices
for Male Circumcision,14,15 pilot implementation studies
using the PrePex device were conducted in all VMMC focus
countries except Ethiopia, Namibia, and Swaziland. The aim
was to establish the feasibility and the acceptability of the
new device for the program, providers, clients, their families,
and partners. The primary objective of the studies was to
assess the safety of PrePex MC procedures conducted by
nurses and clinical ofﬁcers during routine service delivery in
adult males. We present results from 3 pilot implementation
studies with a total sample size of 1401.
METHODS
Study Design
In all 3 countries, a single arm, open label, prospective,
cohort study was conducted. In Mozambique, a total of 504
males aged 18 to 49 were recruited at one ﬁxed study site, José
Macamo General Hospital in Maputo. In South Africa, 315
adult males (18–45) were recruited at VMMC sites at Witbank
Hospital, Tsakane Clinic, and Zuzimpilo Clinic in Johannes-
burg. An additional 83 adolescent participants (13–17 years)
were recruited at Tsakane and Zuzimpilo. In Zambia, the
PrePex study was conducted among 499 adult males (18–49
years) at 2 ﬁxed VMMC clinics in the capital city of Lusaka,
which were managed by the Society for Family Health (SFH).
PrePex circumcisions were conducted at existing ﬁxed
VMMC sites where conventional surgical VMMC services
were also provided to facilitate immediate access to care in case
of a serious adverse event (SAE) requiring surgical correction.
Written informed consent was sought from all participants in
the different studies and VMMC staff at all sites were trained in
the PrePex procedure per standard protocol provided by the
manufacturer. PrePex circumcisions were conducted by nurses,
clinical associates, and doctors in South Africa, by nurses in
Mozambique, and by nurses and clinical ofﬁcers in Zambia.
Follow-up of study participants differed across the 3
country studies. All review days were referenced to postplace-
ment with the day of placement set at day 0. Device removals
were scheduled at day 7 at all sites. In Mozambique,
participants were asked to return for additional clinical visits
at days 28 and 49, thereafter participants were asked to return
to the clinic for review until complete wound healing.
Interviewers also made follow-up calls to clients on days 14
and 21. In South Africa, study participants were followed up
after device removal weekly at the clinic until complete
wound healing was observed. In Zambia, the ﬁrst 50
participants were followed intensely at 5 follow-up visits
(days 9, 14, 21, 35, and 42), and the remaining men were
followed at days 7 and 42 per routine service delivery. Men
were encouraged to return to the clinic at any time if they
faced challenges or had concerns in all studies.
Outcome Measures
Outcome measures included:
• Frequency and percentage of adverse events (AEs). Per WHO
recommendations,15 we measured the rate of moderate and
severe AEs. All AEs were recorded and classiﬁed as mild,
moderate, and severe according to the PSI/COSECSA AEs
Action Guide for VMMC as modiﬁed for other PrePex pilot
implementation studies.16 AEs included those due to pain
during the PrePex process; measured using a visual analog
score with a range of 0–10, where 0 corresponds to “no pain
at all” and 10 to “worst pain imaginable.” Clients were shown
pictograms for 6 different rating levels. The pain assessments
were made at speciﬁed time points throughout the study.
• Frequency and percentage of device displacements and self-
removals were included under AEs and device malfunctions.
Difﬁcult placements were recorded separately from AEs.
• Proportion of screening failures and reasons for participant
exclusion.
• Time taken for placement and removal of the device. In
Mozambique and Zambia, time of device placement was
recorded from application of the anesthetic cream to cutting
of the veriﬁcation thread, whereas in South Africa, time of
device placement was measured from the start of cleaning
of the genitalia, to the client leaving the operating table
with the device applied.
• Frequency and proportion of men healed at different time
points. A participant was classiﬁed as healed if the wound
was completely epithelialized. Whether complete wound
healing had occurred was assessed through clinical exam-
ination on agreed review dates or through telecommunica-
tion. If the clients had not healed on the speciﬁc review
date, they were asked to return for review weekly until
complete wound healing was achieved.
Recruitment and Eligibility
All 3 studies followed similar study and data collection
procedures. Males were recruited from the surrounding areas of
VMMC PrePex study sites. All clients received information
during individual and group sessions on VMMC and were
offered 2 options, either standard surgical procedure or PrePex
device male circumcision. Those choosing surgery received the
conventional surgical standard of care (nonresearch). Individual
consent for inclusion in the PrePex study was obtained from
those interested in participating in the study, parent consent and
participant assent were obtained from adolescent participants in
the South Africa study. Clients were offered HIV testing, and all
clients were then screened for PrePex eligibility.
Inclusion and Exclusion Criteria
The following inclusion and exclusion criteria were
used in all 3 studies.
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Inclusion Criteria
Men aged 18–49 (Mozambique and Zambia) and 13–45
years (South Africa), uncircumcised, consents/assents to the
PrePex male circumcision procedure, HIV-negative—in good
general health and clinically free of sexually transmitted
infections (STI)—provides contact information, agrees to
active follow-up, providing location information and a cell
phone number.
Exclusion Criteria
Penis did not ﬁt any of the 5 PrePex sizes; medical
contraindication, cognitive, or psychiatric impairment as
determined by staff, genital anatomic abnormalities or/and
active genital disease/infections, evidence of partial circum-
cision, or scariﬁcation.
Ethics Approvals
The study protocol in Mozambique was approved by
the Mozambican National Bioethics Committee (Reference
73/CNBS/13 dated April 8, 2013), by the Johns Hopkins
University IRB (Reference JHSPH IRB-FC IRB No:
00004637 dated January 2, 2013) and by the CDC Center
for Global Health (May 28, 2013). The study received
administrative approval from the Ministry of Health (MOH)
(Reference 591/GMS/002/2012). The study in South Africa
was approved by the University of the Witwatersrand’s
Human Research Ethics Committee and South African pro-
vincial level research committees. The study in Zambia was
reviewed and approved by the IRBs of FHI 360 and the
University of Zambia Biomedical Research Ethics Committee
(UNZABREC), as well as by the Zambian MOH and the
Zambian Medicines Regulatory Authority (ZAMRA), which
approved importation of the devices into Zambia.
RESULTS
Study Populations, Eligibility
Baseline data of clients, sample sizes, study sites,
timing of the studies are included in Table1.
Mozambique
608 clients attending the VMMC clinic at José Macamo
General Hospital in Maputo were consented, enrolled in the
study, interviewed, and screened for eligibility. Of these, 104
(17.1%) were determined to be ineligible and 504 (82.9%)
had the PrePex device placed. The 104 clients screened out
included 65 clients with HIV seropositive status, 12 clients
with phimosis and narrow foreskin, 3 with symptomatic STIs,
1 with mental impairment, 17 participants were ineligible
because of other social reasons challenging follow-up, and an
additional 6 participants had to be excluded after reveriﬁca-
tion of their age, as they were below 18 years of age.
South Africa
A total of 454 males, 339 (74.7%) adults (18–45 years),
and 94 (25.3%) adolescents (13–17 years) were assessed for
eligibility to receive the PrePex device across the 3 VMMC/
PrePex study sites. Of those assessed, 21 (4.6%) refused
PrePex circumcision during the consenting process; 433
(95.4%) consented and then screened, of whom 35 (7.7%)
failed the screening process due to medical or social reasons.
Of the 35 ineligible clients, 24 (68.6%) were adults and 11
(31.4%) were adolescents (13–17 years).
Zambia
A total of 546 men who presented at the 2 Lusaka SFH
VMMC clinics agreed to undergo circumcision by PrePex.
Of these men, 500 (91.6%) received PrePex male circum-
cision. There were 18 (3.3%) exclusions due to phimosis,
hypospadias, narrow foreskin, or other anatomic condition;
9 (1.7%) with symptomatic STI; 17 (3.1%) with other
medical contraindications; one client (0.2%) withdrew
consent; and 1 (0.2%) did not receive PrePex for an
unspeciﬁed reason. One HIV-infected man inadvertently
received PrePex, and he was excluded from the analysis,
although he was followed for healing and safety in the same
fashion as other participants.
Safety
Adverse Events
Table 2 summarizes moderate and severe AEs that
occurred during the studies. A total of 26 (1.9%) participants
experienced one or more moderate or severe AEs. Of the 26
participants who experienced at least one AE, 20 experienced
one AE (either severe or moderate), three men had two severe
AEs, one man had one severe and one moderate AE and two
men reported three AEs, one severe and two moderate each.
TABLE 1. Baseline Data of Clients, Sample Sizes, Study Sites, Timing of the Study
Mozambique South Africa Zambia
Sample size 504 315 adults and 83 adolescents 499
Participants age
range, yrs
18–49 18–45 18–49
13–17
Mean age 24 yrs (IQR: 18–26) Adults: 26 yrs (IQR: 22–30) 25 yrs (IQR: 21–30)
Adolescents: 16 yrs (IQR: 15–16.5)
PrePex study setting One ﬁxed site: José Macamo General
Hospital in Maputo, Mozambique
Three ﬁxed VMMC clinics in Gauteng
Province (ZuziMpilo and Tsakane
Clinics) and in Mpumalanga Province
(Witbank Hospital)
Two ﬁxed VMMC clinics in Lusaka,
Zambia: New Start YWCA and
Chachacha Male Circumcision Centres
Timing of the study May 2013–July 2013 July 2013–May 2014 October 2013–April 2014
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The moderate and severe AE rates for the 3 country studies
were reported as follows: Mozambique 5/504 (1.0%), South
Africa 11/398 (2.8%), and Zambia 10/499 (2.0%). There
was no signiﬁcant difference in the AE rate among
the countries.
A total of 34 distinct moderate (19) and severe (15)
adverse events were observed across the 3 studies. There were
8 device displacements and/or self-removal, requiring correc-
tive surgery, all were classiﬁed as severe adverse events. All
resolved with subsequent uneventful healing. The other
severe AEs included 3 distinct cases of bleeding (2 of which
required suturing), 3 cases of edema, and one case of wound
dehiscence. There were 19 distinct cases of moderate AEs,
which included bleeding, edema, wound dehiscence, infec-
tion, voiding problems, and delayed wound healing. All
reported AEs resolved with appropriate clinical intervention
and without permanent sequelae.
Pain-Related AEs
Table 3 summarizes pain-related moderate and severe
AEs. A total of 182/1401 (13%) moderate and 239/1401 (17%)
severe pain-related AEs were reported, respectively. A higher
number of pain-related AEs were reported from Mozambique
and South Africa. Mozambique reported 300/504 (59.5%) and
South Africa reported 139/398 (34.9%) moderate or severe
pain-related AEs, whereas Zambia reported 2/499 (0.4%)
moderate pain-related AEs, most of which occurred at
device removal.
Placement and Removal Procedure
The mean time for the placement procedure varied
between 2.7 and 3.1 minutes in Mozambique, 7 minutes in
South Africa, and 2.4 minutes in Zambia. The mean time for
removal of the device and necrotized foreskin varied between
1.9 and 2.7 minutes in Mozambique, 2.4 minutes in South
Africa, and 4.7 minutes in Zambia.
Time to Complete Wound Healing
Among adult study participants in South Africa and
Zambia, respectively, 43/315 (13.5%) and 277/499 (55.5%)
men were observed as completely healed at day 42 (Fig. 1).
By day 49, 422/501 (84.2%), 122/315 (38.7%), and 438/499
(87.8%) of participants from Mozambique, South Africa, and
Zambia, respectively, were reported to be completely healed.
By day 56, 445/501 (88.8%) and 305/315 (96.7%) of the
adult participants from Mozambique and South Africa,
respectively, had completely healed.
Figure 2 shows that there was a signiﬁcant difference
in time to healing between adults and adolescents in the
South African study, with adolescents healing faster than
adults (P , 0.001).
TABLE 2. Number of Distinct Moderate and Severe Adverse Events Among All Participants With Device Placement, by Country
(N = 1401) and Moderate and Severe Adverse Events Rate (%) by Country
Adverse Events by Severity Mozambique, N = 504 (%) South Africa, N = 398 (%) Zambia, N = 499 (%) Total, N (%)
Moderate
Bleeding 2/504 (0.4) 2/398 (0.5) 2/499 (0.4) 6/1401 (0.4)
Edema 0/504 (0) 1/398 (0.3) 2/499 (0.4) 3/1401 (0.2)
Wound dehiscence 0/504 (0) 0/398 1/499 (0.2) 1/1401 (0.1)
Others (infection, voiding problems, delayed healing) 0/504 (0) 5/398 (1.3) 4/499 (0.8) 9/1401 (0.6)
Moderate AE rate 2/504 (0.4) 8/398 (2.0) 4/499* (0.1.8) 14/1401 (1.0)
Severe
Device displacement/self-removal 3/504 (0.6) 3/398 (0.8) 2/499 (0.4) 8/1401 (0.6)
Wound dehiscence 0/504 (0) 0/398 (0) 1/499 (0.2) 1/1401 (0.1)
Bleeding 0/504 (0) 0/398 (0) 3/499 (0.6) 3/1401 (0.2)
Edema 3/499 (0.6) 3/1401 (0.2)
Severe adverse events rate 3/504 (0.6) 3/398 (0.8) 6/499† (1.2) 12/1401 (0.9)
Total severe/moderate AEs 5/504 (1.0) 11/398 (2.8) 10/499‡ (2.0) 26/1401 (1.9)
*A total of 9 moderate discrete AEs were recorded in 4 participants.
†A total of 9 severe discrete AEs were recorded in 6 participants.
‡A total of 18 discrete moderate and severe adverse events were recorded in Zambia (total AE count). The 18 severe/moderate adverse events were reported among 10 participants
or 2.0% (95% CI: 1.0% to 3.7%) of the men; 4 men had one AE, 4 men had 2 AEs and 2 men had 3 AEs.
TABLE 3. Pain-Related Moderate and Severe Adverse Events Among all Participants With Device Placement by Country and
Moderate and Severe Pain-Related Adverse Events Rate (%) by Country
Pain-Related AEs
Mozambique South Africa Zambia Total
N = 504 % N = 398 % N = 499 % N %
Moderate AEs 108/504 21.4 72/398 18.1 2/499 0.4 182/1401 13.0
Severe AEs 192/504 38.1 47/398 11.8 239/1401 17.0
Moderate/severe pain-related AE rate 300/504 59.5 119/398 29.9 2/499 0.4 421/1401 30.0
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Loss to follow-up of study participants, who should
have presented at the day 42 review visit but were not seen,
was 28/315 (9%) and 25/499 (5%) in South Africa and
Zambia, respectively. In Mozambique, loss to follow-up at
day 49 was 23/501 (4.6%).
DISCUSSION
The moderate/severe AE rates from the 3 different
studies in Mozambique (1.0%), South Africa (2.6%), and
Zambia (2.0%) are close to the AE rate reported in other
PrePex safety studies conducted in Rwanda,9,17–19 Ugan-
da,20,21 and Zimbabwe,11–13 whereas overall moderate/severe
AE rate in a recent study in Kenya22 was slightly higher
(5.9%) including more device displacements/self-removals
than the 3 studies here described (0.4% in Mozambique, 0.6%
in South Africa, and 0.8% in Zambia).
Although the rate of displacements and self-removals was
low (8/1401, 0.6%), they are not only severe but are deﬁned as
serious adverse events, necessitating surgical circumcision by
sleeve or dorsal slit method. Programs must ensure that surgical
circumcision backup is readily available to handle such cases.
Special attention must be placed on appropriate counseling and
adequate information about the risk related to sexual intercourse
with device in situ and self-tampering with the device.
The overall moderate/severe AE rate in the 3 PrePex
studies described here is also comparable with those reported
for the surgical male circumcision procedure either with the
forceps guided method1,2,23 or the dorsal slit method3,24 and is
also similar to the AE rate in adults using the ShangRing.25,26
Most of 1401 PrePex procedures were conducted by
midlevel providers (nurses, clinical ofﬁcers, and clinical
associates). This could be a potential advantage over male
circumcision surgery, especially in VMMC priority countries
where task shifting of the male circumcision procedure is not
yet policy, as it could reduce the costs and reduce the human
resources capacity challenges that VMMC programs in these
countries are facing.
There were variations in placement and removal times
over the different studies, which are explained by different
timing protocols and by the different levels of experience by
the providers involved. The mean total time (placement
preparation and procedure time and removal preparation and
procedure time) in each of the 3 studies was lower than the
procedure time for conventional surgery (19.2 minutes).10 This
represents another advantage over the surgical procedure in
terms of efﬁciency, which could result in higher client turnover
and outputs, thus reduced per VMMC unit costs.
Owing to the fact that wound healing after PrePex
procedure is by secondary intention, the time required for
complete healing across the 3 studies was at least about 1 week
longer than that reported after surgical VMMC, for which more
than 90% of men are judged healed by day 42.27 In these studies,
84.2%, 38.7%, and 87.8% of adult participants had complete
wound healing on day 49 in Mozambique, South Africa, and
Zambia, respectively. In previous studies conducted in Rwanda
and Zimbabwe, mean time to complete healing was up to 2
weeks longer than with surgery, and the mean healing time after
placement recorded over 5 PrePex studies was 42.3 days, which
is comparable with the healing time that was recorded in the 3
studies presented here.10 Time to complete wound healing was
signiﬁcantly shorter in adolescents than in adults in the study
from South Africa. Similar ﬁndings were observed in the PrePex
adolescents study in Zimbabwe where mean time to complete
wound healing was 31.9 days (SD = 5.5) in adolescents (13–17
years) as compared with 42.3 days (SD = 7.8) in adults.26
Longer healing time could potentially result in higher risk of
HIV acquisition in circumcised men during the healing period
and represents also a higher risk of HIV transmission to female
partners of recently circumcised HIV positive men.
The PrePex device was safe and effective for circumci-
sion in adult men and a small cohort of adolescent males in
South Africa. The studies provide better understanding of some
of the reported advantages of the method, including ease of task
shifting to nonphysician cadres of providers; increased efﬁ-
ciency due to reduced procedure time; and lower risk of
bleeding and infection as compared with surgery. Nevertheless,
the studies reported high rates of pain-related AEs, especially
at device removal, which needs to be addressed. Pain-
related AEs were much more frequently reported in
Mozambique and in South Africa as compared with
Zambia. This might be explained by the use of different
pain-related AE classiﬁcations used across the studies and
variability of interpretation by providers. Use of topical
FIGURE 1. Cumulative proportion of adult participants with
complete wound healing at 42, 49, and 56 days after device
application.
FIGURE 2. Cumulative proportion of adult and adolescent
participants with complete wound healing at 42, 49, and 56
days post device application, South Africa.
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anesthetic cream in combination with oral analgesics at
device removal should be evaluated. Pain related to the
device procedure could lead to reduced acceptability of the
device among potential clients and needs to be addressed
urgently. It is important to note that backup surgery by an
experienced provider proﬁcient in the dorsal slit or sleeve
method needs to be available because of the risk of device
displacement and self-removal by the client. Additional
research to better understand barriers and motivators for
uptake of PrePex will inform demand creation and commu-
nications strategies to promote device VMMC. Results
from acceptability studies that were nested within the pilot
implementation studies for which data are presented here
are described separately to this manuscript.27 The PrePex
device VMMC performed well in all 3 country studies and
is safe when used alongside routine VMMC surgical service
delivery. The device has the potential to facilitate wide-
spread scale-up of safe VMMC in sub-Saharan Africa.
We note the following study limitations:
Interpretation of complete healing and pain scores was
subjective and could vary between MC providers and clinics as
well as across countries.28 This explains the high variability for
the pain-related AEs reported from the 3 countries. Because of
the different methodologies in measuring timing of the proce-
dures by country, it is impossible to compare timing across the 3
countries. The most important weakness of the study was the
incompleteness of postremoval follow-up of study participants
across all studies. Follow-up of each participant was intended
until complete healing could be conﬁrmed, but a high percentage
of the men were either lost to follow-up after device removal or
exited the study without certiﬁcation of complete healing.
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